Research programme: c-Met inhibitors - Eli Lilly

Drug Profile

Research programme: c-Met inhibitors - Eli Lilly

Alternative Names: SGX 126

Latest Information Update: 04 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SGX Pharmaceuticals
  • Developer Eli Lilly
  • Class Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 31 Dec 2011 No development reported - Preclinical for Solid tumours in USA (Parenteral)
  • 24 Oct 2008 Pharmacodynamics and pharmacokinetics data from preclinical trials in Cancer presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)
  • 20 Aug 2008 SGX Pharmaceuticals has been acquired by Eli Lilly
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top